NPCE - NeuroPace Inc Debt to Book Capitalization Ratio

Corporate company logo of NeuroPace, Inc. (NPCE)

NeuroPace, Inc. (NPCE) develops an advanced neurostimulator that functions as a pacemaker for the brain, treating epilepsy through continuous activity analysis. Profit growth is driven by the expansion of the implant network and service maintenance, which reduces R&D costs. Success is based on physician adoption of the method and insurance reimbursements, with the indicator standing at 5.81. This chart of current share prices confirms these fundamental theses.

NeuroPace, Inc. - NPCE Debts to Book Capitalization (period 07/04/2022 - 10/27/2026)
Flagship merchandise of NeuroPace Medical

This indicator assesses the total liabilities-to-equity ratio, determining the company's reliance on external financing and its overall financial stability. The current value of 5.81 within the historical debt-to-capitalization metrics allows investors to evaluate the leverage risk of NeuroPace, Inc. (NPCE) as it scales the RNS system in the neuromodulation market for refractory epilepsy therapy.

Competitors of NeuroPace, Inc.

DXCM: Debts to Book Capitalization|penumbrainc.com - Debts to Book Value|Debt to Book Capitalization Ratio Novanta (NOVT)|HAE - Debt to Net Assets Ratio|INSP: Debts to Book Capitalization|PRCT (Procept) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CONMED Corporation CNMD|Debts to Book Capitalization Ratio pulsebiosciences.com|InMode - Debts to Book Capitalization|Debts to Book Value Picard Medical Corp PMI|Debt to Book Value SRDX (Surmodics Corp)|SENS - Debts to Book Capitalization|Debt to Book Value Tactile Systems Technology Inc. TCMD|SNWV - Debt to Book Capital|Outset Medical - Debts to Book Capitalization|Electromed (ELMD) - Debts to Net Assets|Debts to Book Capitalization LNSR|Debt to Book Value AVITA Medical Inc (RCEL)|Profound Medical Corp. (PROF) - Debt to Book Value|Debt to Net Assets Ratio BDMD (bairdmed.com)|EDAP TMS - Debt to Book Capitalization Ratio|Debt to Book Value Apyx Medical Corp APYX|ICCM (IceCure Medical, Ltd.) - Debts to Book Capitalization|LUNG - Debts to Book Value|Debts to Book Capitalization telabio.com|CytoSorbents Corporation (CTSO) - Debt to Book Value Ratio|SRTS: Debts to Book Capitalization|Debts to Net Assets Zynex Medical|Debts to Book Capitalization ECOR (electroCore, Inc.)|Debt to Book Value vicarioussurgical.com (RBOT)|Debts to Book Capitalization IINN (Inspira Technologies)|seastarmedical.com - Debts to Book Capitalization|IRIX - Debt to Book Capitalization Ratio|Intelligent Bio Solutions (INBS) - Debt to Book Capitalization Ratio|Debt to Book Value beyondair.net XAIR|Profusa, Inc (PFSA) - Debt to Net Assets Ratio|Debts to Book Capitalization SSKN (STRATA Skin Sciences Inc.)|Debts to Book Value GCTK|NAOV: Debt to Book Capitalization Ratio|Debt to Net Assets Venus Concept Inc VERO|Debt to Book Value NUWE (CHF Solutions)|Debts to Book Capitalization Aethlon Medical Corp AEMD|Debts to Book Capitalization ASXC (TransEnterix)|AVGR: Debts to Net Assets|Debt to Book Capitalization Ratio Biosig Technologies (BSGM)|CUTR (Cutera Inc.) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio KNW|Debt to Book Value Inari Medical Corp|Nevro Corp. - Debts to Book Capitalization|Debts to Book Value RSLS (reshapelifesciences.com)|SILK - Debt to Book Capitalization Ratio